Table 1 Mutations inside the BCR-ABL kinase domain and resistance to medicines received in patients
From: The importance of personalized medicine in chronic myeloid leukemia management: a narrative review
IMA | Nilotinib | Dasatinib | Bosutinib | Ponatinib | Mutation location |
|---|---|---|---|---|---|
M244V Q252H | M244V L248V Q252H Y253H/F E255K/V | M244V Q252H E255K/V | M244V Q252H Y253F Y253H | M244V E255K/V | P-Loop |
L387F H396P/R | L387F H396P/R | H396P/R | H396P | H396P | A-Loop |
M351T E355G/D/A F359V/C/I | M351T F359V/C/I | F359C/V | M351T F359V | M351T | C-Loop |
E123Q | E123Q T212R | T212R | Â | Â | SH2 (outside ABL KD) |
E275K D276G F486S | D276G V299L F486S | V299L | M343T | Â | Other |
F317L/VI/C | F317L/V/C | F317L/VI/C | Â | T315I F317L | DBS |
| Â | Â | Y253H/E255V Y253H/T315I | Â | Q252H/T315I F317L/E255V T315I/M351T T315I/F359V T315I/H396R F317L/E459K | Compound mutation |
L248V L248R G250E Y253H/F E255K/V | L248R G250E | L248R L248V G250E | L248R G250E E255K E255V | Â | P-Loop |
| Â | Â | Â | Â | H396R | A-Loop |
| Â | Â | Â | Â | Â | C-Loop |
T212R | Â | Â | Â | Â | SH2 (outside ABL KD) |
E279K F311L | Â | Â | V299L | Â | Other |
T315I T315V | T315I T315V | T315I T315A T315V | T315I T315V T315R F317V | Â | DBS |
L248R/F359I | L248R/F359I | L248R/F359I M351T/E255K | L248R/F359I | L248R/F359I Y253H/T315I T315I/G250E E255V/T315I T315I/M351T T315I/L384M T315I/E453K F317L/F359V/C T315I/E459K F317L/L384M | Compound mutation |